Contacts

Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development

July 9, 2019

Under their collaborative agreement, MedinCell and Teva have selected a lead formulation for the longacting injectable mdc-ANG. Preclinical studies are expected to start this quarter.

mdc-ANG complements a range of antipsychotic products in development based on MedinCell’s
technology, including a first research product in clinical Phase 3 studies and another research product
in the late stages of preclinical development.

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.